Mode
Text Size
Log in / Sign up

Forty independent genetic loci associated with acute chest syndrome occurrence in sickle cell disease patientsIdentifying Genetic Markers Linked to Chest Problems in Sickle Cell Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that 40 independent genetic loci are associated with acute chest syndrome in sickle cell disease patients.

This meta-analysis investigated genetic variants associated with the occurrence and recurrence of acute chest syndrome (ACS) in patients with sickle cell disease of predominantly African ancestry. The analysis identified 40 independent genetic loci associated with ACS occurrence (p < 10^-5) and 39 independent loci associated with ACS recurrence (p < 10^-5).

Additional molecular QTL analysis identified 42 SNP-protein and 8 SNP-metabolite associations (p < 10^-3). Survival analysis indicated a lower survival probability among young patients with ACS recurrence compared to controls or cases of ACS occurrence. The authors noted that while 40 loci were identified for occurrence, none of the SNPs reached the genome-wide threshold in that specific meta-analysis.

These findings suggest that the more extreme phenotype of ACS recurrence may provide a more informative phenotype for risk prediction and therapeutic targeting. However, the results indicate only associations between genetic loci and ACS, and do not establish a causal relationship. Clinical application is currently limited by the lack of specific hazard ratios for survival outcomes.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the genetic architecture of complications in sickle cell disease. While prior coverage has focused on transfusion safety, management of chronic pain, and surgical outcomes for retinopathy, this study specifically identifies genetic loci associated with acute chest syndrome. It provides a molecular basis for the risk of ACS recurrence, which may inform future risk prediction models for these patients.

Doctors are looking for better ways to manage sickle cell disease, a condition that can cause severe lung issues. This study looked at the genetic makeup of patients to see why some develop chest problems while others do not. By looking at many patients, researchers found specific spots in the DNA that are linked to these complications.

One of the most serious issues is when a patient experiences a repeat of these chest problems. The study found that patients who experience these issues a second time have a much lower chance of survival. This suggests that identifying high-risk patients early could help doctors provide better care and more frequent monitoring.

Researchers also found links between these genetic markers and changes in proteins and chemicals in the body. These findings could lead to new ways to treat the disease. By understanding the underlying biology, doctors may be able to target specific pathways to prevent severe complications before they happen.

What this means for you:
Genetic markers can help identify high-risk patients who are more likely to suffer from repeated chest complications.

Common questions

What did the study find about genetic markers and chest complications?

The study identified 40 independent genetic loci associated with the first occurrence of acute chest syndrome. For patients who experienced the condition again, 39 other independent loci were identified. These markers are linked to the genetic makeup of patients with sickle cell disease.

Who was most at risk during the study?

The study found that young patients who experienced a recurring case of acute chest syndrome had a lower survival probability compared to those who had it for the first time or to the control group.

How do these findings help patients with sickle cell disease?

By identifying these genetic markers, doctors may eventually be able to better predict who is at risk for severe complications. This could help in creating more specific treatment plans for patients facing the most severe forms of the disease.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Sickle cell disease (SCD) results from homozygosity or compound heterozygosity for a single point mutation in the beta hemoglobin gene. Despite carrying the same underlying causal mutation, patients exhibit highly heterogeneous clinical outcomes. Acute chest syndrome (ACS) is one of the leading causes of mortality in SCD. In this study, we aimed to identify genetic variants associated with ACS occurrence and recurrence (>5 episodes) in two SCD cohorts (OMG-SCD and Walk-PHaSST) of predominantly African ancestry and characterize their downstream molecular consequences. Although none of the SNPs reached the genome-wide threshold in the occurrence meta-analysis, we identified 40 independent genetic loci with p <10-5. However, the recurrence GWAS in OMG-SCD, which compared individuals with no prior history of ACS to individuals with a history of >5 episodes, identified one genome-wide significant locus along with 38 other independent loci with p <10-5. Survival analysis suggested lower survival probability among young ACS recurrence cases compared to controls or occurrence cases. Furthermore, molecular QTL analysis of ACS recurrence identified 42 SNP-protein and eight SNP-metabolite associations with p <10-3. Pathway and enrichment analysis identified secretory, platelet/hemostatic, and complement-mediated pathways, confirming the complex and heterogeneous pathophysiology of ACS. This study highlights the importance of a well-defined phenotype for identification of risk loci and elucidates the complex interplay of hemolytic, inflammatory, and cellular organization pathways that warrants further evaluation through large-scale multi-omic studies of SCD patients. Ultimately, the more extreme phenotype of ACS recurrence may be a more informative phenotype for analysis, risk prediction, and therapeutic targeting.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.